Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
News|Articles|October 7, 2013
Waters Introduces Mass Detector for Chromatography Separations
Author(s)Pharmaceutical Technology Editors
The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations.
The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations. The detector, introduced on Oct. 7 by Waters Corp., is now shipping worldwide.
Designed as a component of a chromatographic system, the ACQUITY QDa Detector is compatible with Waters ACQUITY UltraPerformance LC, ACQUITY UltraPerformance Convergence Chromatography, Alliance high performance liquid chromatography and Waters supercritical fluid chromatography and LC-based purification systems.
The system is designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. It features automated sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. The detector generates the high quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a photodiode array (PDA) detector.
The ACQUITY QDa Detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information; quantifies compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection,
The ACQUITY QDa Detector is available for separations systems running Empower 2 and 3 Chromatography Data System software, including enterprise deployment with automated qualification. The ACQUITY QDa Detector is also available now for MassLynx 4.1 Mass Spectrometry Software.
Source:
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
Formulation AI From Zero Data: AAPS PharmSci 360 2026
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5